Annuncio pubblicitario
Italia markets close in 6 hours 49 minutes

  • FTSE MIB

    34.268,91
    +282,01 (+0,83%)
     

  • Dow Jones

    38.852,27
    +176,59 (+0,46%)
     

  • Nasdaq

    16.349,25
    +192,92 (+1,19%)
     

  • Nikkei 225

    38.835,10
    +599,03 (+1,57%)
     

  • Petrolio

    78,70
    +0,22 (+0,28%)
     

  • Bitcoin EUR

    59.768,24
    -985,07 (-1,62%)
     

  • CMC Crypto 200

    1.330,01
    -35,11 (-2,57%)
     

  • Oro

    2.324,10
    -7,10 (-0,30%)
     

  • EUR/USD

    1,0767
    -0,0007 (-0,06%)
     

  • S&P 500

    5.180,74
    +52,95 (+1,03%)
     

  • HANG SENG

    18.479,37
    -98,93 (-0,53%)
     

  • Euro Stoxx 50

    4.977,69
    +20,73 (+0,42%)
     

  • EUR/GBP

    0,8584
    +0,0012 (+0,14%)
     

  • EUR/CHF

    0,9771
    +0,0015 (+0,16%)
     

  • EUR/CAD

    1,4722
    +0,0006 (+0,04%)
     

Anika to Issue Third Quarter 2023 Financial Results on Thursday, November 2, 2023

Anika Therapeutics Inc.
·1 minuto per la lettura
Anika Therapeutics Inc.
Anika Therapeutics Inc.

BEDFORD, Mass., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2023 financial results after the close of the market on Thursday, November 2, 2023 and hold its investor conference call on the same day, at 5:30 p.m. ET to discuss its financial results and business highlights.

The conference call can be accessed by dialing 1-844-826-3035 (toll-free domestic) or 1-412-317-5195 (international) and providing the conference ID number 10182980. A live audio webcast will be available in the Investor Relations section of Anika's website, www.anika.com. An accompanying slide presentation also can be accessed via the Anika website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika

Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management, Regenerative Solutions, Sports Medicine and Arthrosurface Joint Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.

ANNUNCIO PUBBLICITARIO

ANIKA, ANIKA THERAPEUTICS and the Anika logo are registered trademarks of Anika Therapeutics, Inc.

For Investor Inquiries:
Anika Therapeutics, Inc.
Mark Namaroff, 781-457-9287
Vice President, Investor Relations, ESG and Corporate Communications
investorrelations@anika.com